A recent double blinded and placebo-controlled clinical trial (ACTT-3) showed no significant difference in patient outcomes with the combination of IFN-β-1a plus remdesivir compared with remdesivir alone, suggesting no clinical benefits of IFN therapy in patients with COVID-19 (23). The gene discussed is IFNA1; the disease is COVID-19.